Results of adoptive immunotherapy clinical trials in Hodgkin lymphoma
| Therapy . | Reference . | Phase . | Patients, n . | Lymphodepletion . | Response . | Most common toxicities . |
|---|---|---|---|---|---|---|
| EBV-specific T cells | Bollard et al38 | 1 | 14 | None | Active disease cohort: ORR 27%; PR 9%; CR 18%; SD 45%. Cohort in remission: 100% disease-free at 10- to 40-mo follow-up | Transient flu-like symptoms (14%) |
| LMP-1/2 specific T cells | Bollard et al37 | 1 | 50 | None | Active disease cohort: ORR 62%; CR 52%; PR 10%; cohort in remission: 2 y EFS 82% | No treatment-related toxicities, although 2 possible inflammatory responses |
| LMP-1/2 specific T cells with DNRII | Bollard et al40 | 1 | 8 | None | Active disease cohort: ORR 43%; PR 14%; SD 57%; patient in remission (n = 1): durable CR up to 2+ years | No treatment-related toxicities |
| Allogeneic LMP-1/2 specific T cells | McLaughlin et al44 | 1 | 26 | None | Active disease: CR 0%; PR 28%; OS of 43% at 2 y; cohort in remission: 2 y EFS 57% at 2 y; 2-y OS 78% | Grade 4 hepatic necrosis in 1/26 (4%) |
| CD30 CAR T cells | Wang et al52 | 1 | 18 | Fludarabine and cyclophosphamide; gemcitabine, mustargen, and cyclophosphamide; or ab-paclitaxel and cyclophosphamide | ORR: 39%; CR: 0%; PR: 39%; SD: 33%. PFS: 6 mo (range: 3-14 mo) | Nausea and vomiting (28%), rash (11%), joint swelling (6%), dizziness (6%), and pneumonitis (6%) |
| CD30 CAR T cells | Ramos et al53 | 1 | 9 | None | ORR: 33%; CR: 33%; SD: 33%; PD: 33%; durable CR up to 2.5+ years | No treatment-related toxicities |
| CD30 CAR T cells | Ramos et al54 | 1/2 | 41 | Bendamustine; bendamustine and fludarabine; or cyclophosphamide and fludarabine | No responses with bendamustine-alone lymphodepletion cohort; responses with fludarabine-based regimen (n = 32): ORR 72%; CR 59%; PR 13%; SD 9%; PD 19% | Rash (48%); grade 1 CRS (24%); grade 3/4 leukopenia (57%), anemia (12%), neutropenia (48%), and thrombocytopenia (26%) |
| CD19 CAR T cells | Svoboda et al58 | Early phase 1 | 4 | Cyclophosphamide | ORR: 50%; CR 25%; PR 25%; SD 25%; PD 25%; at 3 mo, 3/4 had PD and the remainder was taken off trial | Fatigue (75%), headache (75%), confusion (50%); no grade 3 or 4 toxicities |
| Therapy . | Reference . | Phase . | Patients, n . | Lymphodepletion . | Response . | Most common toxicities . |
|---|---|---|---|---|---|---|
| EBV-specific T cells | Bollard et al38 | 1 | 14 | None | Active disease cohort: ORR 27%; PR 9%; CR 18%; SD 45%. Cohort in remission: 100% disease-free at 10- to 40-mo follow-up | Transient flu-like symptoms (14%) |
| LMP-1/2 specific T cells | Bollard et al37 | 1 | 50 | None | Active disease cohort: ORR 62%; CR 52%; PR 10%; cohort in remission: 2 y EFS 82% | No treatment-related toxicities, although 2 possible inflammatory responses |
| LMP-1/2 specific T cells with DNRII | Bollard et al40 | 1 | 8 | None | Active disease cohort: ORR 43%; PR 14%; SD 57%; patient in remission (n = 1): durable CR up to 2+ years | No treatment-related toxicities |
| Allogeneic LMP-1/2 specific T cells | McLaughlin et al44 | 1 | 26 | None | Active disease: CR 0%; PR 28%; OS of 43% at 2 y; cohort in remission: 2 y EFS 57% at 2 y; 2-y OS 78% | Grade 4 hepatic necrosis in 1/26 (4%) |
| CD30 CAR T cells | Wang et al52 | 1 | 18 | Fludarabine and cyclophosphamide; gemcitabine, mustargen, and cyclophosphamide; or ab-paclitaxel and cyclophosphamide | ORR: 39%; CR: 0%; PR: 39%; SD: 33%. PFS: 6 mo (range: 3-14 mo) | Nausea and vomiting (28%), rash (11%), joint swelling (6%), dizziness (6%), and pneumonitis (6%) |
| CD30 CAR T cells | Ramos et al53 | 1 | 9 | None | ORR: 33%; CR: 33%; SD: 33%; PD: 33%; durable CR up to 2.5+ years | No treatment-related toxicities |
| CD30 CAR T cells | Ramos et al54 | 1/2 | 41 | Bendamustine; bendamustine and fludarabine; or cyclophosphamide and fludarabine | No responses with bendamustine-alone lymphodepletion cohort; responses with fludarabine-based regimen (n = 32): ORR 72%; CR 59%; PR 13%; SD 9%; PD 19% | Rash (48%); grade 1 CRS (24%); grade 3/4 leukopenia (57%), anemia (12%), neutropenia (48%), and thrombocytopenia (26%) |
| CD19 CAR T cells | Svoboda et al58 | Early phase 1 | 4 | Cyclophosphamide | ORR: 50%; CR 25%; PR 25%; SD 25%; PD 25%; at 3 mo, 3/4 had PD and the remainder was taken off trial | Fatigue (75%), headache (75%), confusion (50%); no grade 3 or 4 toxicities |